Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biden Says Administration Working With Vaccine Manufacturers on Contingency Plans to Combat New Variant

11/29/2021 | 12:51pm EST

By Tarini Parti

President Biden said his administration was working with officials at Pfizer Inc., Moderna Inc. and Johnson & Johnson to develop contingency plans for vaccines or boosters in case they are needed to combat the Omicron variant of the coronavirus.

Mr. Biden said at this time officials don't think such additional measures will be needed.

He also said he will soon release a strategy outline for how the administration plans to deal with Covid-19 this winter, adding that the plans would focus on more vaccinations, boosters and testing rather than lockdowns.

"This variant is a cause for concern, not a cause for panic," he said.

Write to Tarini Parti at tarini.parti@wsj.com

(END) Dow Jones Newswires

11-29-21 1251ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -5.77% 147.5 Delayed Quote.-39.28%
JOHNSON & JOHNSON -0.23% 164.87 Delayed Quote.-3.40%
MODERNA, INC. -4.45% 160.07 Delayed Quote.-34.04%
PFIZER, INC. -2.33% 52.79 Delayed Quote.-8.47%
All news about MODERNA, INC.
04:17pModerna's Valuation Has Come 'Back to Earth,' Become More Reasonable, BofA Securities S..
MT
03:30pSmall children getting less sick from Omicron; Genetic mutation protects against severe..
RE
02:56pBooster shots needed against omicron, CDC studies show
AQ
02:36pU.S. studies highlight the need for COVID boosters to fight Omicron
RE
01:21pCDC : Vaccines less effective against Omicron, but still reduce risk for serious illness
AQ
12:21pUBS Initiates Coverage on Moderna With Neutral Rating, $221 Price Target
MT
09:29aBofA Securities Upgrades Moderna to Neutral From Underperform, Adjusts Price Target to ..
MT
01/20Moderna says aims to name 'country of choice' for COVID vaccine production in Africa so..
RE
01/20EMA Says Spikevax Product Information To Be Updated To Include Paraesthesia As Rare Sid..
RE
01/20EMA : Assessment of whether vaccination can cause capillary leak syndrome (is ongoing for ..
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 563 M - -
Net income 2021 11 122 M - -
Net cash 2021 9 774 M - -
P/E ratio 2021 6,33x
Yield 2021 -
Capitalization 67 921 M 67 921 M -
EV / Sales 2021 3,31x
EV / Sales 2022 2,20x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 167,52 $
Average target price 276,00 $
Spread / Average Target 64,8%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831
CELLTRION, INC.-17.42%19 342